• Onco-Innovations entered three loan agreements for up to CAD 280,000 in aggregate financing.
• Two shareholder loans total up to CAD 80,000; 15% annual interest; repayable on demand; prepayable without penalty.
• Separate CAD 200,000 loan from Chief Medical Officer Islam Mohamed; 1% monthly interest; two CAD 100,000 tranches due by Sept. 13, 2026, Nov. 13, 2026.
• Overdue amounts accrue an additional 2% monthly interest; prepayment requires 2% fee, interest through maturity.
• Shareholder-loan proceeds earmarked for working capital; CAD 200,000 loan restricted to specified third-party R&D vendors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via TheNewswire (Ref. ID: 202607151800TNWSWRCACNPR_____1AD4F1NgO) on July 15, 2026, and is solely responsible for the information contained therein.